Genetic polymorphisms of the Fc gamma receptors (FcγR) IIa and IIIa have been implicated in the rate of HIV-1 disease progression, but results are inconsistent. We aimed to determine the association between these polymorphisms and disease progression in a cohort of HIV-1 seroconverters from Mombasa, Kenya. Neither FcγRIIa nor FcγRIIIa genotypes were predictive of set point viral load, viral load increase, CD4 decline, or HIV-1 disease progression (time to CD4 count <200 cells/mm3, death, or treatment initiation). Our results suggest that FcγR polymorphisms might not be an important indicator of viral control and disease progression in this population.
Get full access to this article
View all access options for this article.
References
1.
RavetchJV and BollandS: IgG Fc receptors. Annu Rev Immunol, 2001; 19:275–290.
2.
Vargas-InchausteguiDA and Robert-GuroffM: Fc receptor-mediated immune responses: New tools but increased complexity in HIV prevention. Curr HIV Res, 2013; 11(5):407–420.
3.
AsmalM, LetvinNL, and Geiben-LynnR: Natural killer cell-dependent and non-dependent anti-viral activity of 2-Cys peroxiredoxin against HIV. Int Trends Immun, 2013; 1(4):69–77.
4.
ClarkMR, ClarksonSB, OryPA, et al.: Molecular basis for a polymorphism involving Fc receptor II on human monocytes. J Immunol, 1989; 143(5):1731–1734.
5.
ClarkMR, StuartSG, KimberlyRP, et al.: A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol, 1991; 21(8):1911–1916.
6.
BruhnsP, IannascoliB, EnglandP, et al.: Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood, 2009; 113(16):3716–3725.
7.
WarmerdamPA, van de WinkelJG, VlugA, et al.: A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol, 1991; 147(4):1338–1343.
8.
ShashidharamurthyR, ZhangF, AmanoA, et al.: Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J Immunol, 2009; 183(12):8216–8224.
9.
AckermanME, DugastA-S, McAndrewEG, et al.: Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b. J Virol, 2013; 87(10):5468–5476.
10.
ForthalDN and MoogC: Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS, 2009; 4(5):388–393.
11.
LambotteO, FerrariG, MoogC, et al.: Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS, 2009; 23(8):897–906.
12.
JiaM, LiD, HeX, et al.: Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression. Clin Exp Immunol, 2013; 171(1):107–116.
13.
ForthalDN, LanducciG, BreamJ, et al.: Fc γ RIIa genotype predicts progression of HIV infection. J Immunol, 2007; 179(11):7916–7923.
14.
PooniaB, KijakGH, and PauzaCD: High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One, 2010; 5(12):e15562.
15.
MartinHL, JacksonDJ, MandaliyaK, et al.: Preparation for AIDS vaccine evaluation in Mombasa, Kenya: Establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res Hum Retroviruses, 1994; 10(Suppl 2):S235–237.
16.
MartinHL, NyangePM, RichardsonBA, et al.: Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis, 1998; 178(4):1053–1059.
17.
LavreysL, BaetenJM, OverbaughJ, et al.: Virus load during primary human immunodeficiency virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis, 2002; 35(1):77–81.
18.
LavreysL, BaetenJM, KreissJK, et al.: Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis, 2004; 189(2):303–311.
19.
EmeryS, BodrugS, RichardsonBA, et al.: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol, 2000; 38(7):2688–2695.
20.
BurchardPR, MalhotraS, KaurP, and TsongalisGJ: Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer Genet, 2013; 206(4):130–134.
21.
LehrnbecherTL, FosterCB, ZhuS, et al.: Variant genotypes of FcgammaRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood, 2000; 95(7):2386–2390.
22.
OumaC, KellerCC, OpondoDA, et al.: Association of FCgamma receptor IIA (CD32) polymorphism with malarial anemia and high-density parasitemia in infants and young children. Am J Trop Med Hyg, 2006; 74(4):573–577.
23.
TaniuchiS, MasudaM, TeraguchiM, et al.: Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. J Clin Immunol, 2005; 25(4):309–313.
24.
BrouwerKC, LalRB, MirelLB, et al.: Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. 2004; 18(8):1187–1194.
25.
RadstakeTRDJ, PetitE, PierlotC, et al.: Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis. J Rheumatol, 2003; 30(5):926–933.
26.
ThabetMM, HuizingaTWJ, MarquesRB, et al.: Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis. Ann Rheum Dis, 2009; 68(11):1775–1780.
27.
LiSS, GilbertPB, TomarasGD, et al.: FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest, 2014; 124(9):3879–3890.
